NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Conditions:   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer;   Non Small Cell Lung Cancer Interventions:   Drug: efineptakin alfa;   Drug: Atezolizumab Sponsors:   NeoImmuneTech;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials